Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed CapitalCHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital. Founded to address urgent unmet needs in rare and life-threatening diseases, Quetzal brings together a team of seasoned executives, scientific pioneers, and biotech & pharmaceutical veterans committed to delivering transformative therapies to patients around the world.
